Seeking Alpha

Idenix (IDIX -0.6%) regains some of yesterday's post-session dip, but still trails the overall...

Idenix (IDIX -0.6%) regains some of yesterday's post-session dip, but still trails the overall market after saying that it's discontinuing its clinical development program for two of its investigational hepatitis C drugs, after the FDA said the treatments would remain on clinical hold. The hold is related to the regulator's heart-safety concerns about rival Bristol-Myers Squibb's (BMY) BMS-986094, a treatment for the liver disease which belongs to the same class of drugs known as nucleotide polymerase inhibitors. 
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|